PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,771.00
Bid: 1,771.00
Ask: 1,771.50
Change: -12.50 (-0.70%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London open: Stocks at one-month high as Vodafone, RBS gain

Fri, 21st Feb 2014 08:47

- Vodafone, RBS and Glaxo provide a lift- IHG, Glencore Xstrata hit by downgrades- FTSE 100 at highest intraday level in monthtechMARK 2,891.98 +0.55%FTSE 100 6,840.31 +0.40%FTSE 250 16,419.58 +0.31% Strong gains from heavyweights Vodafone, RBS and GlaxoSmithKline gave UK markets a boost on Friday with stocks rising to levels not seen in a month.The FTSE 100 was trading 0.4% higher at 6,840 early on, its highest intraday level since January 22nd.A decent performance on Wall Street last night has helped to spur buying this morning, as US indices turned around after a poor start as data showed that manufacturing activity Stateside rose to a four-year high."I think this clearly highlights the fact that the market is still generally bullish and is once again looking for any excuse to buy," said Market Analyst Craig Erlam from Alpari.After a data-heavy week, today's session is set to be a little quieter on the macro front, though UK retail sales and public-sector borrowing figures will catch investors' attentions this morning.Vodafone, RBS and Glaxo provide a liftTelecoms titan Vodafone was making decent gains this morning with shareholders set to receive a windfall from the company's sale of its 45% stake in Verizon Wireless. The $130bn cash and shares deal is set to complete today.RBS was higher amid reports that the bank will announce plans to slash as many as 30,000 jobs, reducing its staff count to the lowest levels in more than 10 years.Pharmaceuticals giant GlaxoSmithKline was higher after European regulators recommended marketing authorisation for umeclidinium, its once-daily treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.Millennium & Copthorne, the FTSE 250 hotel firm, jumped after reporting record revenues and profits for 2013 as fourth-quarter results were boosted by the one-off sale of the bulk of the Glyndebourne development in Singapore.Sector peer InterContinental Hotels Group, however, was trading in the red after Credit Suisse lowered its recommendation to 'underperform', pointing out that the shares are trading within just 4% of their all-time high at a price-to-earnings ratio of 23.Glencore Xstrata was also lower after JPMorgan Cazenove downgraded its rating on the stock to 'neutral', saying that its peers have overtaken it in terms of capital returns potential.FTSE 100 - RisersVodafone Group (VOD) 236.00p +2.79%Royal Bank of Scotland Group (RBS) 361.70p +1.69%ARM Holdings (ARM) 962.50p +1.64%Persimmon (PSN) 1,459.00p +1.53%Prudential (PRU) 1,370.00p +1.11%Barclays (BARC) 258.05p +1.10%Aviva (AV.) 473.40p +1.09%BAE Systems (BA.) 404.70p +1.07%British Land Co (BLND) 702.50p +0.93%Compass Group (CPG) 925.50p +0.93%FTSE 100 - FallersGlencore Xstrata (GLEN) 333.05p -2.17%InterContinental Hotels Group (IHG) 1,934.00p -2.08%Smiths Group (SMIN) 1,366.00p -1.73%IMI (IMI) 1,544.00p -1.34%Mondi (MNDI) 1,032.00p -1.24%Anglo American (AAL) 1,536.50p -1.13%Morrison (Wm) Supermarkets (MRW) 239.50p -1.07%Fresnillo (FRES) 975.00p -1.02%easyJet (EZJ) 1,732.00p -0.92%Antofagasta (ANTO) 942.50p -0.84%FTSE 250 - RisersMillennium & Copthorne Hotels (MLC) 598.00p +4.64%Essentra (ESNT) 875.00p +3.55%IP Group (IPO) 221.00p +3.22%Petra Diamonds Ltd.(DI) (PDL) 170.10p +3.03%Centamin (DI) (CEY) 51.70p +2.48%Morgan Advanced Materials (MGAM) 341.40p +1.88%Laird (LRD) 328.30p +1.77%Informa (INF) 531.00p +1.72%Afren (AFR) 156.10p +1.63%AL Noor Hospitals Group (ANH) 917.50p +1.61%FTSE 250 - FallersVesuvius (VSVS) 462.70p -1.91%Telecity Group (TCY) 669.50p -1.69%Electra Private Equity (ELTA) 2,439.00p -1.45%Dechra Pharmaceuticals (DPH) 675.50p -1.39%Xaar (XAR) 1,095.00p -1.35%Evraz (EVR) 82.10p -1.20%Crest Nicholson Holdings (CRST) 375.00p -1.19%Debenhams (DEB) 74.25p -0.93%UK Commercial Property Trust (UKCM) 78.00p -0.83%Domino's Pizza Group (DOM) 543.50p -0.82%BC
More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.